GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adverum Biotechnologies Inc (NAS:ADVM) » Definitions » Net Margin %

Adverum Biotechnologies (Adverum Biotechnologies) Net Margin %

: 0.00% (As of Dec. 2023)
View and export this data going back to 2014. Start your Free Trial

Net margin is calculated as Net Income divided by its Revenue. Adverum Biotechnologies's Net Income for the three months ended in Dec. 2023 was $-23.71 Mil. Adverum Biotechnologies's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Adverum Biotechnologies's net margin for the quarter that ended in Dec. 2023 was 0.00%.

The historical rank and industry rank for Adverum Biotechnologies's Net Margin % or its related term are showing as below:

ADVM' s Net Margin % Range Over the Past 10 Years
Min: -25794.4   Med: -3847.92   Max: -1940.53
Current: -3254.58


ADVM's Net Margin % is ranked worse than
83.74% of 1027 companies
in the Biotechnology industry
Industry Median: -163.32 vs ADVM: -3254.58

Adverum Biotechnologies Net Margin % Historical Data

The historical data trend for Adverum Biotechnologies's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adverum Biotechnologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -25,794.40 - -1,940.53 - -3,254.58

Adverum Biotechnologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -807.11 - - -

Competitive Comparison

For the Biotechnology subindustry, Adverum Biotechnologies's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adverum Biotechnologies Net Margin % Distribution

For the Biotechnology industry and Healthcare sector, Adverum Biotechnologies's Net Margin % distribution charts can be found below:

* The bar in red indicates where Adverum Biotechnologies's Net Margin % falls into.



Adverum Biotechnologies Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Adverum Biotechnologies's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-117.165/3.6
=-3,254.58 %

Adverum Biotechnologies's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-23.714/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adverum Biotechnologies  (NAS:ADVM) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Adverum Biotechnologies Net Margin % Related Terms

Thank you for viewing the detailed overview of Adverum Biotechnologies's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Adverum Biotechnologies (Adverum Biotechnologies) Business Description

Traded in Other Exchanges
Address
100 Cardinal Way, Redwood CIty, CA, USA, 94063
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
Executives
C. David Nicholson, director 103 CHILDS ROAD, BASKIN RIDGE NJ 07092
Setareh Seyedkazemi officer: Chief Development Officer C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL DRIVE, REDWOOD CITY CA 94063
Linda M Rubinstein officer: Chief Financial Officer 25861 INDUSTRIAL BLVD, HAYWARD CA 94545
Peter Soparkar officer: Chief Legal Officer C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Brigit Riley officer: Chief Scientific Officer 100 CARDINAL WAY, REDWOOD CITY CA 94063
Laurent Fischer director, officer: CEO and Director C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Richard Beckman officer: Chief Medical Officer C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Nancy E Pecota officer: Principal Accounting Officer ARADIGM CORPORATION, 3929 POINT EDEN WAY, HAYWARD CA 94545
John Rakow officer: SVP, Genl Counsel, Acting CFO C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Rupert D'souza officer: Chief Financial Officer C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Dawn Svoronos director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Soo Hong director C/O ADVERUM BIOTECHNOLOGIES, INC., 800 SAGINAW DRIVE, REDWOOD CITY CA 94063
Rabia Gurses Ozden director C/O AKOUOS, INC., 645 SUMMER STREET SUITE 200, BOSTON MA 02210
James Paul Scopa director 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Julie Clark officer: Chief Medical Officer C/O ADVERUM BIOTECHNOLOGIES, INC., 800 SAGINAW DRIVE, REDWOOD CITY CA 94063

Adverum Biotechnologies (Adverum Biotechnologies) Headlines

From GuruFocus

Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

By Value_Insider Value_Insider 12-06-2022

Adverum Biotechnologies to Present at Upcoming Investor Conferences

By sperokesalga sperokesalga 02-27-2023

Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

By Stock market mentor Stock market mentor 01-18-2023